DalsnaFinance

Akston's NGF-Targeting Ambifect® Candidates Demonstrate Clinically Meaningful Osteoarthritis Pain and Function Improvements Comparable to Bedinvetmab in Head-to-Head Canine Study

Markets PR Newswire By PR Newswire 07 Jul 2026 13:30 1 min read
Akston's NGF-Targeting Ambifect® Candidates Demonstrate Clinically Meaningful Osteoarthritis Pain and Function Improvements Comparable to Bedinvetmab in Head-to-Head Canine Study

Data presented at the 2026 American College of Veterinary Internal Medicine (ACVIM) Forum showed that AKS-548d and AKS-734 induced sustained anti-NGF antibody responses, functional neutralization of NGF binding to TrkA, clinically meaningful reductions in canine osteoarthritis pain, and...

Data presented at the 2026 American College of Veterinary Internal Medicine (ACVIM) Forum showed that AKS-548d and AKS-734 induced sustained anti-NGF antibody responses, functional neutralization of NGF binding to TrkA, clinically meaningful reductions in canine osteoarthritis pain, and...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.